TEVOGEN BIO HOLDINGS INC. overview

Key Takeaways: Since its founding in 2020, Tevogen Bio has developed a significant asset portfolio, and kept expenditures under $40 million, a fraction of the industry norm. Tevogen’s success would not be possible without its passionate team united by a common vision. Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution. Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion...

WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen. In tandem with this announcement,...

Tevogen Bio is a fully functional biotech, with investor-valued assets over $10 billion achieved with under $40 million in spending. Approximately 78% of Tevogen Bio's common stock is held by company officers. WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is...

Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline. Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process. 5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia. WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a...

WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce the appointment of Anthony Tarantino as its new Patient Advocate. Tarantino, a well-known leader in firefighter safety and community advocacy, brings extensive experience in representing and...

Current timeline for drug development is 10-12 years and costs approximately $1-3 billion. Tevogen’s approach has the potential to shorten timelines and substantially reduce costs. Tevogen’s AI initiative, Tevogen.AI , will pursue two key objectives, applying machine learning to existing processes to accelerate drug development and lower costs, and using Microsoft’s industry leading AI tools to develop proprietary algorithms designed to decode the relationship between genetics and T cells....

Regained compliance without effecting a reverse stock split Tevogen Bio CEO reaffirms his commitment to preserve shareholder value WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announced today that on October 28, 2024, it received written notice from the...

CD8 Technology Services, LLC (“CD8 Technology”) to provide turn-key facility for Tevogen Bio Reinforces Tevogen Bio’s commitment to preserving shareholder value Expected to further enhance Tevogen Bio’s ambitious growth agenda WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious...